NF-kappaB inhibitors impair platelet activation responses

Area of Science:

• Platelet biology
• Molecular signaling
• Transcription factors

Background:

• Platelets, anucleated cells, express transcription factors for non-genomic functions.
• Nuclear factor-kappa B (NF-kappaB) is a key regulator of survival, proliferation, and inflammation genes.

Purpose of the Study:

• To investigate the role of NF-kappaB in platelet physiology.
• To evaluate NF-kappaB's involvement in platelet activation, inflammation, and tumor progression.

Main Methods:

• Immunofluorescence, Western blotting, and ELISA to detect NF-kappaB and IkappaBalpha in platelets.
• Assessing platelet function (PAC-1 binding, fibrinogen binding, spreading, aggregation) with NF-kappaB inhibitors (BAY 11-7082, Ro 106-9920).
• Measuring thrombin-stimulated responses (ATP release, TXB2 formation, P-selectin expression, ERK phosphorylation, cPLA2 activity) and in vivo platelet aggregation in mice.

Main Results:

• Platelets express IkappaBalpha and NF-kappaB; thrombin stimulation causes IkappaBalpha degradation and NF-kappaB p65 binding.
• NF-kappaB inhibitors reduced integrin alpha(IIb)beta3 activation, platelet spreading, and aggregation induced by various agonists (except arachidonic acid).
• Inhibitors also decreased thrombin-induced ATP release, TXB2 formation, P-selectin expression, ERK phosphorylation, and cPLA2 activity; ADP-induced aggregation was impaired in vivo.

Conclusions:

• NF-kappaB acts as a novel mediator of platelet responses.
• Blocking platelet function via NF-kappaB inhibitors could be beneficial in anti-tumor and anti-inflammatory therapies.